We report a retrospective analysis of 11 children with Down syndrome (DS) treated by SCT in eight German/ Austrian SCT centres. Indications for transplantation were acute lymphoblastic leukaemia (N ¼ 8) and acute myeloid leukaemia (N ¼ 3). A reduced intensity conditioning (RIC) containing 2 Gy TBI was given to two patients, another five received a myeloablative regimen with 12 Gy TBI. Treosulphan or busulphan was used in the remaining four children. Four of eleven (36%) patients are alive. All of them were treated with a myeloablative regimen. One of the four surviving children relapsed 9 months after SCT and is currently receiving palliative outpatient treatment. The main cause of death was relapse (5/11). Two children died of regimen-related toxicity (RRT), one from severe exfoliative dermatitis and multiorgan failure after a treosulphan-containing regimen, the other from GvHDrelated infections after RIC. Acute GvHD of the skin was observed in 10 of 10 evaluable patients, and chronic GvHD in 4 of 8. Our data show that DS patients can tolerate commonly used, fully myeloablative preparative regimens. The major cause of death is relapse rather than RRT resulting in an event-free survival of 18% and over all survival of 36%.
Introduction
Children with Down syndrome (DS) are at 10-to 30-fold increased risk of developing AML or ALL. 1, 2 In reviews of multicentre studies for treatment of acute leukaemia, 1.5-2.1% of children with ALL 3,4 and 3.5-9.8% of children with AML [5] [6] [7] [8] had a diagnosis of DS. For children with high risk or recurrent leukaemia, SCT is an effective therapy and often the only potentially curative treatment option. Nevertheless, the number of children with DS who received SCT is significantly smaller than would be expected. 9 Reasons for considering DS patients as suboptimal SCT candidates might include coexistence of conditions associated with DS, increased toxicity during induction therapy, and fear of conditioning intolerance with high therapy-related mortality during SCT. Increased chemotherapy-related toxicity is reported in children with DS and acute leukaemia. In particular, high-dose MTX is associated with severe mucositis and profound bone marrow aplasia leading to life-threatening infections. 3 Reports on SCT in children with DS are limited and are mainly released from SCT centres in the United States. Initially, data on SCT in four children with DS was discouraging with high transplant-related mortality. 10 Despite an increased risk for severe regimen-related toxicities 11 it has been reported that DS patients can tolerate conventional SCT. 9, 12, 13 The largest and most detailed report was published by Rubin et al. 11 in 1996 summarizing 27 patients with regard to conditioning, early toxicity, GvHD prophylaxis and survival. Since then, no comprehensive surveillance on SCT in DS patients has been released apart from single case reports. Many factors such as conditioning regimens, supportive therapy and strategies of graft manipulation have changed during the last decades leading to generally improved outcome after SCT.
In this report, we retrospectively reviewed 11 children with DS and acute leukaemia transplanted in German and Austrian SCT centres. The primary aim of the survey was the assessment of early regimen-related toxicity and mortality and its retrospective comparison to experiences published earlier. The secondary aim was the documentation of GvHD and leukaemia-free survival.
Patients, materials and methods

Survey
We identified patients with DS who suffered from acute lymphoblastic or myeloid leukaemia and underwent allogeneic SCT using the paediatric registry of SCT in Germany (PRST). Additionally, transplant centres were contacted directly, and missing patients' details and information were obtained. By comparing the recruited patients with the database of the ALL-BFM study registry all patients could be verified. Therefore, we are confident of having identified all DS patients undergoing SCT between 1996 and 2006. The retrospective survey revealed that 11 patients with DS and acute leukaemia were treated with SCT during the study period.
Patient characteristics and therapy prior SCT Presenting features of patients including sex, age, diagnosis and remission status at SCT are summarized in Table 1 Characteristics of SCT Features of SCT including donor, graft, preparative regimen and GvHD prophylaxis are depicted in Table 1 . Five children received a graft from a HLA-matched sibling, qfour from a HLA-matched unrelated donor, one from a HLA-matched mother (with one allele mismatch at the HLA-C locus) and one from a haploidentical mother.
Results
Regimen-related toxicity
Three of eleven patients (27%) suffered from significant early toxicity including exfoliative dermatitis, multiorgan failure, pancreatitis, pulmonary oedema and severe stomatitis (patient nos. 3, 9 and 6 as summarized in Table 2 ). However, only one patient (no. 3) died of regimen-related toxicity (RRT) during the first 100 days after transplantation. Early toxicity described in all other patients was considered to be within the expected range.
Engraftment
One patient died on day þ 14 prior to neutrophil engraftment. All other patients showed neutrophil engraftment between days þ 9 and þ 29. Platelet recovery was observed between days þ 9 and þ 28.
Chimaerism
Data are not available for patient no.11. and the child that died prior to neutrophil engraftment (patient no.3). Out of the remaining nine patients six achieved full donor-derived haematopoietic chimaerism. The remaining three patients developed a mixed haematopoietic chimaerism. One progressed to graft failure and was rescued after receiving an autologous marrow back up (patient no. 2). One child relapsed (no. 8), one died of sepsis related to chronic GvHD (no. 1).
GvHD
A relatively high rate of acute GvHD (aGvHD) was observed with 10/10 patients (100%) experiencing aGvHD of the skin as illustrated in Table 2 . Patient no. 3 could not be evaluated for GvHD since he died from multiorgan failure early after SCT. All 8/10 patients suffering from skin GvHD Xgrade II or more, received systemic steroids for treatment of aGvHD. Chronic GvHD (cGvHD), always involving the skin, was described in four patients. Three of eleven patients had to be excluded from the evaluation for cGvHD either because they died before day þ 100 or graft failure occurred. Thus, four of eight patients could be identified with cGvHD.
Outcome At the time of this report four patients (36%) are alive 9, 12, 40 and 63 months after SCT ( Table 2 ). The major cause of death is relapse rather than RRT resulting in an eventfree survival of 18% and an overall survival of 36%. All but one of the relapsed patients died 3, 7.5, 8.5, 13 and 20 months after SCT, respectively. Two children died of transplant-related complications. One child suffered from exfoliative dermatitis and multiorgan failure early after a treosulphan/melphalan-based preparative regimen, one from cGvHD-related sepsis. This child was conditioned with a RIC 14 containing 2 Gy TBI and 150 mg m À2 fludarabine. One surviving patient experienced graft failure 3 months after SCT and was rescued with an autologous back up graft, another suffered from relapse 9 months after SCT with poor prognosis regarding survival. The other two living children are in good clinical condition although one suffers from cGvHD of the skin. Three of the surviving patients with ALL underwent a TBI-containing preparative regimen (12 Gy), one child with AML received busulphan instead.
Stem cell transplantation in Down syndrome B Meissner et al Importantly, the main cause of death was relapsed leukaemia (5/11) rather than transplant-related mortality (2/11) with only a single patient dying of regimen-related toxicity during the first 100 days after SCT.
These data support the observation made by Renson et al. 9 that outcomes of DS children treated with SCT (43% survival) do not differ significantly from those of non-DS children. Nevertheless, the two largest surveys, so far (Rubin et al.:
11 27 patients, Renson et al.: 9 16 patients), revealed early transplant-related toxicity and not relapse as main cause of death. Rubin et al.
11 estimated a 39% cumulative risk of death due to non-leukaemic mortality at 3 years, whereas there was a 75% chance of freedom from relapse 3 years after SCT.
We hypothesize that the discrepancies regarding treatment-related mortality (TRM) and relapse rates between our report (TRM 18%, relapse rate 55%) and previous studies are mainly caused by improved supportive care strategies during transplant and more accurate HLA typing in the context of transplant procedures from unrelated donors. Additionally, improved survival of the first 100 days after SCT and a potential selection bias for patients prone to relapse due to tight eligibility criteria for SCT given by the ALL-BFM-SCT consensus guidelines might have resulted in high relapse rates. For comparison, the However, comparisons should be interpreted with caution due to the small number of patients and the heterogeneity of our cohort. The majority of our children were transplanted with commonly used regimens. No child died of early toxicity following etoposide or cyclophosphamide combined with 12 Gy TBI. Of the three patients who received a busulphanbased conditioning, two died of relapse and one is alive but rejected the haploidentical graft. It might be reasonable to conclude that patients with DS can tolerate commonly used myeloablative regimens with TBI or busulphan.
There might be a rationale for avoiding MTX for GvHD prophylaxis because of the known increased MTX toxicity seen in children with DS. However, the dose of MTX used as GvHD prophylaxis (3-4 Â 10-15 mg m À2 per dose À1 ) is significantly smaller than the doses commonly used for chemotherapy (0.5-1 g m
À2
). In the present study, a correlation between the use of MTX and severity of toxicity is difficult to evaluate because of a rather low occurrence of severe RRT after SCT. 10/10 patients (100%) developed acute GvHD of the skin in our series. Similarly, a relatively high incidence of cGvHD (4/8, 50%), mainly involving the skin, was observed in our cohort when compared to general paediatric transplant recipients. [15] [16] [17] These incidences are twice as high as in non-DS children (Christina Peters, personal communications). This might be an argument against a less-intensive GvHD prophylaxis.
Within the observational period, 4970 children with ALL were registered within the German/Austrian part of the BFM-ALL network (covering 80% of children diagnosed with ALL in Germany and 100% in Austria): 142 (2.9%) of them were DS patients and 506/4970 (10.2%) non-DS children underwent SCT in first remission (CR1). Three of 117 children with DS (2.6%) are registered within the German/Austrian part of the BFM network for having received SCT in CR1. Therefore, the number of transplanted patients with DS that underwent SCT in CR1 seems to be low. The authors have to conclude that probably not all patients with DS qualifying for SCT might have undergone this treatment option. The reasons for this can be the subject of speculation only. However, this was an important incentive for trying to readdress the issue of SCT in children with DS in this study.
In summary, the present cohort of patients undergoing SCT further supports the notion that children with DS can survive SCT with a relatively low incidence of early transplant related mortality. Our observations suggest the use of the same conditioning regimens in DS patients that are given to non-DS children. A high incidence of skin GvHD and rather low early transplant-related mortality seems to emphasize the importance of an intensive regimen for GvHD prophylaxis. However, it is important to emphasize that definite conclusions should be drawn carefully due to small numbers, the retrospective character of the report, missing controls and the heterogeneity of the cohort.
